Document:

Letter Agreement Regarding Change In Control Benefits

 EXHIBIT 10.2 
 [Urologix letterhead] 
 July 14, 2008 
 Dear Greg: 
 Although your employment is “at will” and may be terminated by you or Urologix at any time for any
reason, Urologix has agreed to provide you with a particular severance pay benefit following a Change in Control in the event your employment is terminated without Cause, or by you for Good Reason. Terms not otherwise defined in this letter (the
“Letter Agreement”) shall have the meaning given such terms on Schedule 1, which is incorporated herein by reference. 
 Specifically, we have
agreed as follows: 
 1. Change in Control. If a Change in Control shall occur and your employment is terminated without Cause, or by you for Good
Reason, within twelve months of a Change in Control, Urologix shall pay you a severance payment in cash in a single sum within sixty (60) days of the date of termination equal to 100% of the sum of your annual target compensation (base salary
and bonus) in effect on such date. In addition, Urologix shall continue the health, dental and life insurance benefits substantially similar to those you are receiving or are entitled to receive prior to your termination for a period of twelve
(12) months. You shall pay the employee’s share of the premiums for such benefits. 
 2. Arbitration. All disputes or claims arising out of
or in any way related to this Letter Agreement, including the making of this Letter Agreement, shall be submitted to and determined by final and binding arbitration under the Rules of the American Arbitration Association. Arbitration proceedings may
be initiated by either of us upon notice to the other and to the American Arbitration Association, and shall be conducted by three arbitrators under the Rules of the American Arbitration Association in Minneapolis, Minnesota, unless we agree to have
the person or persons to serve as arbitrators within thirty (30) days of delivery of the list of proposed arbitrators by the American Arbitration Association, then, at the request of either of us, the three arbitrators shall be selected at the
discretion of the American Arbitration Association. 
 3. Entire Agreement. This Letter Agreement constitutes our entire agreement and supersedes all
prior discussions, understandings and agreements with respect to the severance benefits which Urologix has agreed to provide to you. This Letter Agreement shall be governed and construed by the laws of the State of Minnesota and may be amended only
in writing signed by both of us. 
 4. Successors. This Letter Agreement shall not be assignable, in whole or in part, by you. This Letter Agreement
shall be binding upon and inure to the benefit of Urologix and its successors and assigns and upon any person acquiring, by merger, consolidation, purchase of assets or otherwise, all or substantially all of the assets and business of Urologix, and
the successor shall be substituted for Urologix under this Letter Agreement. 

 Fluet Greg 
 July 14, 2008

 Page 2 
 If this Letter Agreement accurately sets forth our
agreement and understanding in regard to these matters, will you please sign this Letter Agreement where indicated below and return the executed letter to me for our files. A separate copy is enclosed for your records. 
  

			
	UROLOGIX, INC.
		
	By:	 	 /s/ Stryker Warren, Jr.

		 	Stryker Warren, Jr.
		 	Chief Executive Officer
	
	READ AND AGREED:
		
		 	 /s/ Greg Fluet

		 	Greg Fluet

 SCHEDULE 1 
 Definition of “Cause”: 
 1. The failure by you to use your best efforts to perform the material duties and responsibilities of your
position or to comply with any material policy or directive Urologix has in effect from time to time. 
 2. Any act on your part which is harmful to the
reputation or business of Urologix, including, but not limited to, conduct which is inconsistent with federal or state law respecting harassment of, or discrimination against, any Urologix employee. 
 3. A material breach of your fiduciary responsibilities to Urologix, such as embezzlement or misappropriation of Urologix funds or properties. 
 4. Your indictment for, conviction of, or guilty plea or nolo contendere plea to a felony or any crime involving moral turpitude, fraud or misrepresentation.

 Definition of “Change in Control”: 
 Change
in Control of Urologix shall mean a change in control which would be required to be reported in response to Item 1 of Form 8-K promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), whether or not
Urologix is then subject to such reporting requirement, including without limitation, if: 
  

	 	(a)	any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange
Act), directly or indirectly of securities of Urologix representing 20% or more of the combined voting power of Urologix’ then outstanding securities; 

  

	 	(b)	there ceases to be a majority of the Board of Directors comprised of (A) individuals who, on the date of this Letter Agreement, constituted the Board of Directors of Urologix;
and (B) any new director who subsequently was elected or nominated for election by a majority of the directors who held such office prior to a Change in Control; or 

  

	 	(c)	Urologix disposes of at least 75% of its assets, other than to an entity owned 50% or greater by Urologix or any of its subsidiaries. 

 Definition of “Good Reason”: 
 Good Reason shall mean,
without your express written consent, any of the following: 
  

	 	(a)	the assignment to you of any duties inconsistent with your status or position as Executive Vice President and Chief Operating Officer of Urologix or a substantial reduction in the
nature or status of your responsibilities from those in effect immediately prior to the Change in Control; 

	 	(b)	a reduction by Urologix of your annual base salary in effect immediately prior to a Change in Control; 

  

	 	(c)	the relocation of Urologix’ principal executive offices to a location outside of the Minneapolis metropolitan area or requiring you to be based anywhere other than
Urologix’ principal executive offices, except for required travel for Urologix business to any extent substantially consistent with your prior business obligations; 

  

	 	(d)	the failure by Urologix to continue to provide you with benefits at least as favorable to those enjoyed by you under Urologix plans which you participated in at the time of the
Change in Control, the taking of any action which would, directly or indirectly, materially reduce any of such benefits or deprive you of any benefit enjoyed at the time of the Change in Control, or the failure to provide you with the number of paid
vacation days to which you are entitled at the time of the Change in Control; provided, however, Urologix may amend any such program so long as such amendments do not reduce any benefits to which you would be entitled upon termination;

  

	 	(e)	the failure of Urologix to obtain a satisfactory agreement from any successor to assume and agree to perform this Letter Agreement.Amendment No. 1 to Rights Agreement

 EXHIBIT 4.1 
 AMENDMENT TO PREFERRED SHARES RIGHTS AGREEMENT 
 THIS AMENDMENT TO THE PREFERRED
SHARES RIGHTS AGREEMENT (this “Amendment”), dated as of July 16, 2008, between Catalyst Semiconductor, Inc., a Delaware corporation (the “Company”), and Computershare Trust Company, N.A., (the “Rights Agent”),
amends that certain Preferred Shares Rights Agreement, dated as of December 21, 2006 (the “Rights Agreement”). 
 WHEREAS, the
Company is entering into an Agreement and Plan of Merger and Reorganization (as the same may be amended from time to time, the “Merger Agreement”) by and between the Company, ON Semiconductor Corporation, a Delaware corporation
(“Parent”) and Centaur Acquisition Corporation, a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”); 
 WHEREAS, the Merger Agreement provides for the acquisition by Parent of the Company by means of a reverse triangular merger of Merger Sub with and into the Company (the “Merger”), as a result of which the Company will become a
wholly-owned subsidiary of Parent, and each outstanding share of the Company’s Common Stock, $0.001 par value (the “Shares”), including restricted shares but excluding Shares beneficially owned by Parent, Merger Sub, or the Company
will be converted into the right to receive a fraction of a share of Parent common stock; and each share of the common stock, $0.001 par value per share, of Merger Sub then outstanding shall be converted into one share of common stock of the
Surviving Corporation; 
 WHEREAS, the Company desires to amend the Rights Agreement in connection with the execution and delivery of the
Merger Agreement; 
 WHEREAS, the Board of Directors of the Company has (i) determined that it is in the best interests of the Company
and its stockholders that the Rights Agreement be amended as set forth below, (ii) approved this Amendment and (iii) authorized its appropriate officers to execute and deliver the same to the Rights Agent; 
 WHEREAS, pursuant to Section 27 of the Rights Agreement, the Company may from time to time supplement or amend the Rights Agreement in accordance
with the provisions of Section 27 thereof and the Company desires and directs the Rights Agent to execute this Amendment; and 
 WHEREAS, the Distribution Date has not yet occurred. 

 NOW, THEREFORE, in accordance with the procedures for amendment of the Rights Agreement set forth in
Section 27 thereof, and in consideration of the foregoing and the mutual agreements herein set forth, the parties hereby agree as follows: 
 1. Section 1(a) of the Rights Agreement is amended by adding the following clause at the end of Section 1(a): 
 “Additionally, ON Semiconductor Corporation, a Delaware corporation (“ON”), or any Affiliate or Associate thereof, notwithstanding anything in this Agreement to the contrary, shall not be deemed to be an “Acquiring
Person (and no Distribution Date or Triggering Event shall be deemed to occur) as a result of (A) the approval, execution or delivery of that certain Agreement and Plan of Merger and Reorganization, dated as of July 16, 2008, by and
between the Company, ON, and Centaur Acquisition Corporation, a Delaware corporation (as the same may be amended from time to time, the “Merger Agreement”), including the approval, execution and delivery of any amendments thereto,
(B) the approval, execution or delivery of those certain voting undertakings by and between the Company, ON and certain stockholders of the Company (the “Voting Undertakings”); (C) the consummation of the Merger (as defined in
the Merger Agreement), (D) the conversion of shares pursuant to the Merger Agreement, (E) the announcement of the Merger Agreement or the Merger (as defined in the Merger Agreement), or (F) the consummation of any other transaction
contemplated by the Merger Agreement.” 
 2. Section 1(r) of the Rights Agreement is amended and restated in its entirety to read
as follows: 
 ““FINAL EXPIRATION DATE” shall mean the earlier to occur of (i) December 31, 2016 or
(ii) immediately prior to the Effective Time of the Merger (as such term is defined in the Merger Agreement).” 
 3.
Section 1(hh) of the Rights Agreement is hereby amended by adding as the final sentence thereto the following: 
 “Notwithstanding
anything in this Agreement to the contrary, no Shares Acquisition Date shall be deemed to have occurred solely as a result of (i) the approval, execution or delivery of the Merger Agreement, including the approval, execution and delivery of any
amendments thereto, (ii) approval, execution or delivery of the Voting Undertakings, (iii) the consummation of the Merger (as such term is defined in the Merger Agreement), (iv) the conversion of shares pursuant to the Merger
Agreement, (v) the announcement of the Merger Agreement or the Merger (as such term is defined in the Merger Agreement), or (vi) the consummation of any other transaction contemplated by the Merger Agreement.” 
 4. Section 26 of the Rights Agreement is hereby amended to update the contact information for the Company, Company counsel and the Rights Agent as
follows: 
 Catalyst Semiconductor, Inc. 
 2975 Stender Way 
 Santa Clara, CA 95054-3214 
 Attention: President 
 With a copy to: 
 O’Melveny & Myers 
 275 Battery
Street, Suite 2600 
 San Francisco, CA 94111 
 Attention: Steve Camahort, Esq. 

 Rights Agent: 
 Computershare Trust Company, N.A. 
 250 Royall Street 
 Canton, MA 02021 
 Attention: Relationship
Management 
 5. A new Section 35 shall be added and shall read as follows: 
 “Section 35. TERMINATION. Immediately prior to the Effective Time (as such term is defined in the Merger Agreement), this Agreement shall be
terminated and all outstanding Rights shall expire.” 
 6. This Amendment shall become effective upon execution of the Merger Agreement
by the Company, Parent and Merger Sub. In the event that the Merger Agreement is terminated by the Company or the Parent in accordance with its terms, the provisions of paragraphs 1, 2, 3, 4 and 5 of this Amendment shall be deemed repealed and
deleted without any further action on the part of the Company or the Rights Agent. 
 7. Except as expressly amended hereby, the Rights
Agreement remains in full force and effect in accordance with its terms. 
 8. This Amendment to the Rights Agreement shall be governed by
and construed in accordance with the laws of the State of Delaware. 
 9. This Amendment may be executed in any number of counterparts and
each of such counterparts shall for all purposes be deemed an original, and all such counterparts shall together constitute but one and the same instrument. 
 10. Except as expressly set forth herein, this Amendment shall not by implication or otherwise alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in
the Rights Agreement, all of which are ratified and affirmed in all respects and shall continue in full force and effect. 
 11. Capitalized
terms used herein but not defined shall have the meanings given to them in the Rights Agreement or the Merger Agreement, as applicable. 
 12. The Company hereby certifies to the Rights Agent that this Amendment is in compliance with Section 27 of the Rights Agreement. 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to the Rights Agreement to be duly
executed as of the day and year first above written. 
  

			
	 CATALYST SEMICONDUCTOR, INC.
 a Delaware
corporation

		
	By:	 	/s/ David Eichler
	Name: 	 	David Eichler
	Title:	 	Chief Financial Officer and Corporate Secretary
	
	 COMPUTERSHARE TRUST COMPANY, N.A.
 as Rights
Agent

		
	By:	 	/s/ Tyler Haynes
	Name:	 	Tyler Haynes
	Title:	 	Managing Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00144-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00144-of-00352.parquet"}]]